29 November 2019

 
 

Integrated care of early stage NSCLC (part I)

It’s no longer a question of surgery for early stage non-small cell lung cancer. Today, we work towards full integration of management options in order to optimise survival at all stages of lung cancer and in some cases to achieve cure.

David Gilligan - Addenbrookes Hospital, Cambridge

Professor David Gillian, Chief Investigator of the UK MRC LU22 trial (pre-operative chemotherapy) opens today’s session on the place of neo-adjuvant and adjuvant chemotherapy for patients undergoing surgery in the era of immno-oncology.

CECILE Le Pechoux - Institut Gustave Roussy, Paris

Chief Investigator of EORTC LungART and radiation oncologist Professor Cecile Le Pechoux discusses the rationale behind post-operative radiotherapy for patients with N2 disease, and it’s role in the tri-modality treatment pathway.

Audience discussion and questions:

What is the best position of radiotherapy in the treatment pathways, with known N2 (before surgery) and incidental N2 (after surgery)?

 

Integrated care of early stage NSCLC (part II)

Wu Yi Long - Guangdong General Hospital, Guang Zhou

Chief investigator of the chinese ADJUVANT trial, Professor Wu Yi Long, a thoracic surgeon will be discussing results of adjuvant EGFR TKI trials in the post-RADIANT setting where discordant results on survival have been reported.

Mary O'Brien - Royal Marsden Hospital, London

Professor Mary O’Brien Chief Investigator of EORTC PEARLS (adjuvant pembrolizumab) will be discussing the rationale of post-operative adjuvant immunotherapy and outlining the current clinical trials evaluating this question.

Valerie Rusch - Memorial Sloan Kettering Cancer Center, New York

Professor Valerie Rusch, Chief investigator of the LCMC3 (neo-adjuvant atezolizumab), Investigator for NA_00092076 (neoadjuvant pembrolizumab) will be discussing the rationale of neo-adjuvant immunotherapy and outlining the current clinical trials evaluating this question.

Enriqueta Felip - Vall d'Hebron Institute of Oncology, Barcelona

A provocative title of a talk was given to Professor Enriqueta Felip, a medical oncologist - with the advancements of immunotherapy, does this treatment have the potential to be the primary treatment for early stage non-small cell lung cancer?

Audience discussion and questions:

 

Integrated care of stage III NSCLC

The first generation of clinical trials in IIIA N2 disease did not have a clear definition of resectable IIIA N2 disease and the PACIFIC trial now divides our clinical management by surgical resectability (but without a clear distinction). This session aims to define where the role of chemo-radiotherapy and surgery now sits in the patient pathway with a working definition “resectable” IIIA N2 disease and where immunotherapy (with chemotherapy and with radiotherapy) features in the management of “unresectable” disease.

Eric Lim - Royal Brompton Hospital, London

Professor Eric Lim, is a thoracic surgeon who has lectured widely on this topic, he Chaired the British Guidelines on Radical Management of Lung Cancer advocating patient choice for surgery versus radiotherapy for local control in conjunction with chemotherapy. He will be discussing the concepts of “resectability” in the PACIFIC era.

Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf

Professor Martin Reck, a medical oncologist and PACIFIC trial investigator, will be presenting the role of immunotherapy in “unresectable” stage III disease and where it fits in the patient pathway.

Corinne Faivre-Finn - Christie Hospital, Manchester

Professor Faivre-Finn is a radiation oncologist and PACIFIC trial investigator, will be discussing the role of radiotherapy in “unresectable” stage III disease.

Audience discussion and questions:

What determines if a stage III cancer is “resectable”?

 

Integrated care of advanced NSCLC

With simultaneous pushing of the boundaries between molecular targeted treatments and immunotherapy, options are increasing for patients with advanced disease, this session provides an overview of the current evidence and insights into future development of treatment strategies.

Tony Mok - Chinese University of Hong Kong, Hong Kong

Professor Tony Mok is a leading medical oncologist in the field of molecular targeted therapy, Chief Investigator of iPASS will be discussing the role of targeted molecular treatments in the era of immuno-oncology.

Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf

Professor Martin Reck, medical oncologist and Chief Investigator of KEYNOTE 24 will be presenting an overview on immunotherapy for advanced disease.

Enriqueta Felip - all d'Hebron Institute of Oncology, Barcelona

Professor Enriqueta Felip, medical oncologist and investigator on KEYNOTE 189 (pembrolizumab plus chemotherapy) reporting synergistic effect in improving lung cancer survival will be presenting her views in this rapidly advancing field for non-squamous and squamous lung cancer (KEYNOTE 407).

Audience discussion and questions:

In patients with actionable targets and high PD-L1 expression, what is the correct sequence of treatment?

 

Integrated care of “oligometastatic” NSCLC

With continuing research advances, clinicians are now tackling more advanced stages of lung cancer. Interest in the field of radical management of metastatic disease is commencing in patients with low tumour burden. This session explores integrated care of advanced disease using immunotherapy as a standard of care augmented by different forms of local consolidation therapy.

Suresh Senan - Amsterdam University Medical Center, Amsterdam

Professor Suresh Senanm radiation oncologist will be discussing the role of radiotherapy (with chemotherapy), available evidence and the trials of radiotherapy in the management of oligometastatic disease.

David Palma - London Health Sciences Centre, Ontario

Dr David Palma, radiation oncologist will be presenting his views on the development of radiotherapy in conjunction with immunotherapy for the management of “oligometastatic” non-small cell lung cancer.

Eric Lim - Royal Brompton Hospital, London

Professor Eric Lim, thoracic surgeon will be discussing the research in surgery for oligometastatic disease that is integrated in today’s standard care of immunotherapy.

Audience discussion and questions:

Is there a working definition of what is a patient with oligometastatic disease?

 

Novel approaches to advanced disease

Research in the field of lung cancer has lead to blockbuster discoveries in the last 10 years, ongoing new and developmental implementation and research strategies are still underway. This session explores the role of population based implementation of targeted treatments and showcases the work of leading researchers in the development of new immunotherapeutic approaches.

Sanjay Popat - Royal Marsden Hospital, London

Dr Sanjay Popat, medical oncologist and UK lead for MATRIX will be discussing the possibilities and challenges of implementing a population based approach for personalised molecular targeted therapy.

Alastair Greystoke - Newcastle University, Newcastle upon Tyne

Dr Alastair Greystoke, medical oncologist will be discussing adoptive T cell therapy for lung cancer.

Sergio Quezada - University College London, London

Professor Sergio Quezada, lead immunologist for TracerX will be discussing new immunotherapeutic approaches for lung cancer.